Inclusion Criteria:

          1. Signed informed consent

          2. 18 years of age or older

          3. Multiple myeloma (MM) diagnosed according to IMWG criteria

          4. Measurable disease (this is defined differently in different arms)

          5. Multiple myeloma relapsed or refractory to treatment (this is defined differently in
             different arms)

          6. Meet certain clinical laboratory criteria

          7. ECOG performance status ≤2

          8. Life expectancy of at least 3 months

          9. For women of childbearing potential, a negative serum or urine pregnancy test prior to
             study treatment.

         10. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile
             (absence of ovaries and/or uterus): agreement to use two methods of contraception one
             of which must be highly effective

         11. For men: agreement to use a barrier method of contraception for 1 month before start
             of study treatment, during the treatment period and for 6 months after the last dose
             of study treatment.

        Exclusion Criteria:

          1. Failure to have fully recovered (i.e. ≤ Grade 1 toxicity) from the effects of prior
             chemotherapy (except for alopecia)

          2. Active graft versus host disease

          3. Treatment with any of the following:

               1. Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment

               2. Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to
                  the initiation of study treatment

               3. Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter

               4. Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to
                  the initiation of study treatment

               5. Radiotherapy within 7 days prior to initiating study treatment

               6. Plasmapheresis within 4 weeks prior to the initiation of study treatment

               7. Tasquinimod at any time

          4. Known central nervous system involvement by myeloma

          5. Diagnosis of smoldering multiple myeloma

          6. Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,
             endocrinopathy, monoclonal protein, and skin changes)

          7. Active plasma cell leukemia

          8. Symptomatic primary (AL) amyloidosis

          9. Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome

         10. Active other malignancy

         11. Major surgery within 4 weeks prior to initiating study treatment

         12. Evidence of severe or currently uncontrolled cardiovascular condition

         13. Ongoing or active systemic infection that requires systemic antibiotic or parenteral
             anti-infective therapy

         14. Active tuberculosis, active hepatitis A, B or C virus infection, or known human
             immunodeficiency virus (HIV) positive

         15. History of pancreatitis

         16. History of malabsorption or other condition that would interfere with absorption of
             study drugs

         17. Systemic treatment within 14 days prior to the initiation of study treatment with
             moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4
             (CYP3A4)

         18. Need for ongoing therapy drug substances of narrow therapeutic range that are
             metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole,
             terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)

         19. Need for ongoing therapy with drug substances of narrow therapeutic range metabolized
             mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)

         20. Ongoing treatment with warfarin, unless the INR is <=3.0.

         21. For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with
             lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis
             prophylaxis

         22. Peripheral neuropathy grade ≥2 (NCI-CTCAE)

         23. Known hypersensitivity to tasquinimod or any excipients in the study treatments

         24. Pregnant or nursing (lactating) women

         25. Any other condition that would, in the Investigator's judgment, contraindicate
             subject's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures

         26. Prior inclusion in this study